Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Birmingham, Alabama


This study is a continued evaluation of the immune response to StaphVAX , a Staphylococcus aureus type 5 and 8 capsular polysaccharide conjugate vaccine, in end-stage renal disease patients, by giving a 3rd and 4th dose to a subset of the participants in the previous efficacy trial. Participants continue to receive the vaccine or placebo in a blinded manner, and are also randomly assigned to 1 of 2 different intervals between the doses. The immunogenicity is measured by the antibodies in the blood, and typical vaccine safety information is also collected.


Inclusion Criteria: - Participation in prior study Nabi-1371 - Written informed consent - Negative serum pregnancy test, where appropriate - Expect to comply with protocol procedures and schedule Exclusion Criteria: - Known HIV - Immunomodulatory drugs - Malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or early stage prostate cancer) - Active infection in the 2 weeks prior to study injection - Serious S. aureus infection within the last 2 months prior to injection - Hypersensitivity to components of StaphVAX



Primary Contact:

Study Director
Matt Hohenboken, MD, PhD
Nabi Biopharmaceuticals

Backup Contact:


Location Contact:

Birmingham, Alabama
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.